• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
tebu-bio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Supplying Discovery Tools

PROTACs: A promising strategy in Drug Development

04/07/2019 by Frédéric Samazan No Comments
Proteasome degrading a protein (red) tagged with polyubiquitin

Thanks to its capability to recruit the natural protein degradation system of a cell, PROTACs (PROteolysis TArgeting Chimera) appears as a very promising technology in cancer therapy and disease treatment. As a distributor of innovative reagents for life science researchers, tebu-bio provides you with all the necessary tools to develop or test your own PROTACs system.

Continue reading
Cell Biology and Signalling

A selection of Proteasomal and De-ubiquitinase inhibitors

13/04/2015 by Ali El Baya, PhD No Comments
In 2014, the U.S. Food and Drug Administration (FDA) approved the proteasome inhibiting drug Velcade (Bortezomib) for the retreatment of adult patients with Multiple Myeloma. My colleague Philippe Fixe discussed the use of Bortezomib in his post Proteasome inhibitor approved by FDA for Myeloma retreatment. In this post, I’d like to give you an overview of the compounds which can be used to inhibit proteasome activity and furthermore the activity of De-ubiquitinases (DUB, Isopeptidases), enzymes which catalyze the de-ubiquitination of ubiquitinated proteins and which are seen as very promising drug targets especially in cancer drug development.
Continue reading
Drug Discovery

15 Ubiquitin – Proteasome inhibitors for cancer research

07/10/2014 by Elodie Monin No Comments

With more than 100 types of cancers affecting any part of the body, cancer is one of the leading causes of death in the world. It has an enormous impact on well-being, both for those with the diagnosis and for those who surround them. Understanding and eventually treating or preventing this diverse group of cell growth diseases has been, and will continue to be a major focus of the medical and research communities.

A variety of popular cancer research tools exists and can be divised into categories. We’ll try to summarize them into few posts. Today, I’d like to focus on inhibitors known to be active on the Ubiquitin/Proteasome Pathway.

Continue reading
Drug Discovery, News

Proteasome inhibitor approved by FDA for Myeloma retreatment

26/08/2014 by Philippe Fixe, PhD No Comments

The U.S. Food and Drug Administration (FDA) has approved Velcade (Bortezomib) for the retreatment of adult patients with Multiple Myeloma who had previously responded to Velcade therapy and relapsed at least six months following completion of prior treatment. (1)

Bortezomib (marketed as Velcade by Millennium Pharmaceuticals Inc.) is a potent and selective Proteasome inhibitor. This di-peptide (formerly called PS-341)  was the first therapeutic proteasome to be tested in humans and approved in the U.S. for treating Multiple Myeloma (2, 3). Besides Multiple Myeloma, Bortezomib was also cleared to treat patients with Mantle Cell Lymphoma.

The proteasome regulates protein expression and function by degradation of ubiquitylated proteins. By interacting with the catalytic site of the 26S proteasome, Bortezomib prevents pro-apoptotic factor degradation thus allowing the activation of apoptosis in malignant cells.

This shows that the importance of the Proteasome / Ubiquitin pathway and small bioactive molecules in Drug Discovery research programs and anti-cancer therapy arsenal.

References

  1. FDA Approves VELCADE® (bortezomib) Retreatment in Patients with Multiple Myeloma (August 2014), – Millennium (A Takeda Oncology Company).
  2. Kane R.C. et al. “Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy” The Oncologist (2003), vol. 8 – no. 6, p508-513. doi: 10.1634/theoncologist.8-6-508.
  3. Velcade (bortezomib) is Approved for Initial Treatment of Patients with Multiple Myeloma (2008) – U.S. Food and Drug Administration (FDA)
    Bortezomib structure Velcade®). Source: Focus Biomolecules.

    Bortezomib structure (Velcade®). Source: Focus Biomolecules.

See also

A selection of ultra-pure, cell permeable and potent Proteasome Inhibitors for R&D purposes:

  • Aclacinomycin A
  • Bortezomib 
  • Carfilzomib (CFZ – marketed under the trade name Kyprolis, Onyx Pharmaceuticals, Inc.)
  • Celastrol
  • Epoxomicin (BU4061T)
  • Lactacystin
  • MG-132
  • NSC-687852/b-AP15

What about you?

Which Proteasome inhibitor are you looking for? Leave a comment on this post or share your thoughts with other readers!

tebu-bio

LAB SERVICES OUTSOURCING

• Protein production

• Plasmid Preps

• 3D Cell Culture
LEARN MORE

Top contributors

Dimitri Szymczak, PhD
Dimitri Szymczak, PhD
  • Adenovirus-based KO
  • New – you know CRISPR, now it’s Prime Editing
Frédéric Samazan
Frédéric Samazan
  • Five new fluorescent probes to easily image live cellular processes
  • Immuno-Oncology: 6 must-haves to boost your projects
Isabelle Nobiron, PhD
Isabelle Nobiron, PhD
  • Accelerate your Biomarker discovery with High Density arrays
  • Want to know more about your Biologics?
Isabelle Topin, PhD
Isabelle Topin, PhD
  • Antibody Purification: Tips and Tricks
  • Monoclonal antibodies – all you need to know about antibody generation
Philippe Fixe, PhD
Philippe Fixe, PhD
  • ChIP for sensitive & fast genomic mapping
  • Recent developments in 3D cell culture hydrogel

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com